Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 10/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 7/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24547960 | 0.85 | CSNK1E (0.46) | CSNK1ECSNK1DKCNK3LPLLIPG | |
| SCHEMBL24553872 | 0.83 | GRM5 (0.45) | CSNK1ECSNK1DKCNK3GRM5 | |
| SCHEMBL29683344 | 0.81 | CSNK1E (0.46) | CSNK1ECSNK1DACKR3DPP4KCNK3 | |
| SCHEMBL24548256 | 0.77 | LPL (0.42) | CSNK1ECSNK1DLPLLIPG | |
| SCHEMBL24554423 | 0.77 | L3MBTL1 (0.43) | CSNK1ECSNK1DL3MBTL1GRM5 | |
| SCHEMBL24553820 | 0.76 | CSNK1E (0.41) | CSNK1ECSNK1DACKR3DPP4GRM5 | |
| SCHEMBL24553855 | 0.75 | KCNK3 (0.42) | CSNK1ECSNK1DKCNK3LPLLIPG | |
| SCHEMBL24547936 | 0.75 | CSNK1E (0.44) | CSNK1ECSNK1DLPLLIPG | |
| SCHEMBL29683101 | 0.74 | CSNK1E (0.40) | CSNK1ECSNK1DACKR3DPP4 | |
| SCHEMBL14844993 | 0.73 | THRB (0.46) | CSNK1ECSNK1DLPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276972-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | GRITSCIENCE BIOPHARMACEUTICALS CO LTD (CN) | 2025-09-04 | — | — | US | disclosed |
| WO-2022127756-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022127756-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276972-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | PACSIN2, CSNK1A1, CSNK1G3 | CSNK1E 4/4885CSNK1D 12/4885ACKR3 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.